New inflammatory indicators for cell-based liquid biopsy: association of the circulating CD44+/CD24− non-hematopoietic rare cell phenotype with breast cancer residual disease.

MLA

Schreier, Stefan, et al. “New Inflammatory Indicators for Cell-Based Liquid Biopsy: Association of the Circulating CD44+/CD24− Non-Hematopoietic Rare Cell Phenotype with Breast Cancer Residual Disease.” Journal of Cancer Research & Clinical Oncology, vol. 149, no. 8, July 2023, pp. 4347–58. EBSCOhost, https://doi.org/10.1007/s00432-022-04330-5.

APA

Schreier, S., Budchart, P., Borwornpinyo, S., Arpornwirat, W., Lertsithichai, P., Chirappapha, P., & Triampo, W. (2023). New inflammatory indicators for cell-based liquid biopsy: association of the circulating CD44+/CD24− non-hematopoietic rare cell phenotype with breast cancer residual disease. Journal of Cancer Research & Clinical Oncology, 149(8), 4347–4358. https://doi.org/10.1007/s00432-022-04330-5

Chicago

Schreier, Stefan, Prapaphan Budchart, Suparerk Borwornpinyo, Wichit Arpornwirat, Panuwat Lertsithichai, Prakasit Chirappapha, and Wannapong Triampo. 2023. “New Inflammatory Indicators for Cell-Based Liquid Biopsy: Association of the Circulating CD44+/CD24− Non-Hematopoietic Rare Cell Phenotype with Breast Cancer Residual Disease.” Journal of Cancer Research & Clinical Oncology 149 (8): 4347–58. doi:10.1007/s00432-022-04330-5.